Helium One Global Ltd Announces Jackson-29 Operational Update
LONDON, GB / ACCESS Newswire / April 4, 2025 / Helium One Global (AIM:HE1), the primary helium explorer in Tanzania with a 50% working interest in the Galactica-Pegasus helium development project in Colorado, USA ('the Galactica Project'), provides an update following the Blue Star Helium (ASX: BNL) ('Blue Star') announcement issued today regarding an update on the Jackson-29 well.
Summary
Details
The intermediate hole section of the well was drilled to approximately 1,110 feet (338m). Subject to weather conditions, the cementing programme will be evaluated, and any excess cement removed. Blue Star will then run the mandatory CBL to confirm good bonding and then drill out into the target Lyons Formation. The well will be TD'd within the Upper Lyons Sandstone Formation (production hole section). This is anticipated to commence early next week.
At TD, the well will be wireline logged after which a wellhead will be fitted followed by flow and pressure readings at the wellhead.
It is anticipated that, upon successful testing at Jackson-29, the well will be completed, ready to be tied-in to production facilities
Contact
Notes to Editors
Helium One Global, the AIM-listed Tanzanian explorer, holds prospecting licences across two distinct project areas, with the potential to become a strategic player in resolving a supply-constrained helium market.
The Rukwa and Eyasi projects are located within rift basins on the margin of the Tanzanian Craton in the north and southwest of the country. These assets lie near surface seeps with helium concentrations ranging up to 10.4% helium by volume. All Helium One's licences are held on a 100% equity basis.
The Company's flagship southern Rukwa Project is located within the southern Rukwa Rift Basin in south-west Tanzania. This project is considered to be entering an appraisal stage following the success of the 2023/24 exploration drilling campaign, which proved a helium discovery at Itumbula West-1 and, following an extended well test, successfully flowed 5.5% helium continually to surface in Q3 2024.
Following the success of the extended well test, the Company flowed significant quantities of helium to surface and filed a Mining Licence ('ML') application with the Tanzania Mining Commission in September 2024. The 480km2 ML has now been offered to the Company and was officially accepted in March 2025.
The Company also owns a 50% working interest in the Galactica-Pegasus helium development project in Las Animas County, Colorado, USA. This project is operated by Blue Star Helium Ltd (ASX: BNL).
Helium One is listed on the AIM market of the London Stock Exchange with the ticker of HE1 and on the OTCQB in the United States with the ticker HLOGF.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Mercialys: Acquisition of Saint-Genis 2, a Leading Shopping Center of Greater Lyon
PARIS, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Mercialys (Paris:MERY): An asset perfectly aligned with Mercialys' ambitions Mercialys announces the acquisition of the Saint-Genis 2 shopping center, located in western Lyon, within a catchment area of 700,000 inhabitants—home to the highest-income households in the city. Greater Lyon stands as the second largest consumer market in France after Paris, ahead of Marseille and Toulouse, where Mercialys already holds major assets. This acquisition fully aligns with the Group's strategy to strengthen its presence in the country's most dynamic regions. Acquired for a total price of €146 million including transfer taxes, the asset offers an immediate yield significantly above the Company's investment criteria and presents substantial medium-term value creation potential. A high-performance, leading-retail destination The center had undergone, a few years ago, a comprehensive renovation and environmental performance upgrade program amounting to €45 million. With almost 100 well diversified retail brands and the second most successful hypermarket in the Auchan group (outside the scope of this transaction), it is the largest shopping center in the western part of the Lyon metropolitan area. Beyond its many strengths, the robustness of its catchment area endows this asset with further optimization potential. Its commercial performance can be enhanced through the re-tenanting and consolidation of its retail mix, aligning it with the Company's standards which boast an average occupancy rate of 98% across its 33 strategic assets. An investment initiating a new momentum for the Company This investment represents a unique opportunity for Mercialys to reinforce its position as a key player in the French retail property sector. Guided by a strategy focused on sustainability and operational excellence, the Company intends to fully leverage the strengths of this asset while pursuing its growth objectives. As part of this transaction, Mercialys was advised by Screeb Notarial Office, Arsène for tax matters, and Haldis for technical due diligence. The seller was represented by Michelez Notarial Office, with BNP Paribas and Morgan Stanley acting as financial advisors. This press release is available on presentation of these results is also available online, in the following section:Investors / News and press releases / Financial press releases About Mercialys Mercialys is one of France's leading real estate companies. It is specialized in the holding, management and transformation of retail spaces, anticipating consumer trends, on its own behalf and for third parties. At December 31, 2024, Mercialys had a real estate portfolio valued at Euro 2.8 billion (including transfer taxes). Its portfolio of 1,927 leases represents an annualized rental base of Euro 169.2 million. Mercialys has been listed on the stock market since October 12, 2005 (ticker: MERY) and has "SIIC" real estate investment trust (REIT) tax status. Part of the SBF 120 and Euronext Paris Compartment A, it had 93,886,501 shares outstanding at December 31, 2024. IMPORTANT INFORMATION This press release contains certain forward-looking statements regarding future events, trends, projects or targets. These forward-looking statements are subject to identified and unidentified risks and uncertainties that could cause actual results to differ materially from the results anticipated in the forward-looking statements. Please refer to Mercialys' Universal Registration Document available at for the year ended December 31, 2024 for more details regarding certain factors, risks and uncertainties that could affect Mercialys' business. Mercialys makes no undertaking in any form to publish updates or adjustments to these forward-looking statements, nor to report new information, new future events or any other circumstances that might cause these statements to be revised. View source version on Contacts Analyst and investor Olivier PouteauTel: +33 (0)6 30 13 27 31Email: opouteau@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
28 minutes ago
- Business Wire
Mercialys: Acquisition of Saint-Genis 2, a Leading Shopping Center of Greater Lyon
Mercialys (Paris:MERY): An asset perfectly aligned with Mercialys' ambitions Mercialys announces the acquisition of the Saint-Genis 2 shopping center, located in western Lyon, within a catchment area of 700,000 inhabitants—home to the highest-income households in the city. Greater Lyon stands as the second largest consumer market in France after Paris, ahead of Marseille and Toulouse, where Mercialys already holds major assets. This acquisition fully aligns with the Group's strategy to strengthen its presence in the country's most dynamic regions. Acquired for a total price of €146 million including transfer taxes, the asset offers an immediate yield significantly above the Company's investment criteria and presents substantial medium-term value creation potential. A high-performance, leading-retail destination The center had undergone, a few years ago, a comprehensive renovation and environmental performance upgrade program amounting to €45 million. With almost 100 well diversified retail brands and the second most successful hypermarket in the Auchan group (outside the scope of this transaction), it is the largest shopping center in the western part of the Lyon metropolitan area. Beyond its many strengths, the robustness of its catchment area endows this asset with further optimization potential. Its commercial performance can be enhanced through the re-tenanting and consolidation of its retail mix, aligning it with the Company's standards which boast an average occupancy rate of 98% across its 33 strategic assets. An investment initiating a new momentum for the Company This investment represents a unique opportunity for Mercialys to reinforce its position as a key player in the French retail property sector. Guided by a strategy focused on sustainability and operational excellence, the Company intends to fully leverage the strengths of this asset while pursuing its growth objectives. As part of this transaction, Mercialys was advised by Screeb Notarial Office, Arsène for tax matters, and Haldis for technical due diligence. The seller was represented by Michelez Notarial Office, with BNP Paribas and Morgan Stanley acting as financial advisors. This press release is available on A presentation of these results is also available online, in the following section: Investors / News and press releases / Financial press releases About Mercialys Mercialys is one of France's leading real estate companies. It is specialized in the holding, management and transformation of retail spaces, anticipating consumer trends, on its own behalf and for third parties. At December 31, 2024, Mercialys had a real estate portfolio valued at Euro 2.8 billion (including transfer taxes). Its portfolio of 1,927 leases represents an annualized rental base of Euro 169.2 million. Mercialys has been listed on the stock market since October 12, 2005 (ticker: MERY) and has 'SIIC' real estate investment trust (REIT) tax status. Part of the SBF 120 and Euronext Paris Compartment A, it had 93,886,501 shares outstanding at December 31, 2024. IMPORTANT INFORMATION This press release contains certain forward-looking statements regarding future events, trends, projects or targets. These forward-looking statements are subject to identified and unidentified risks and uncertainties that could cause actual results to differ materially from the results anticipated in the forward-looking statements. Please refer to Mercialys' Universal Registration Document available at for the year ended December 31, 2024 for more details regarding certain factors, risks and uncertainties that could affect Mercialys' business. Mercialys makes no undertaking in any form to publish updates or adjustments to these forward-looking statements, nor to report new information, new future events or any other circumstances that might cause these statements to be revised.
Yahoo
29 minutes ago
- Yahoo
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025 Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announces that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a result of this review the Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 40 positions, representing a potential of ~24% of all positions. "With strong data emerging from MP0533 and MP0712, our priority is to develop these assets which can provide most value for patients and shareholders. The plan to right-size the organization extends our cash reach into 2028, supporting both the development of our clinical assets and advancement of new products into the pipeline. We recognize the contribution that all of our talented employees have made to Molecular Partners and thank them as we take this difficult decision. The Board and I believe this is the right strategic path for the company to help secure its future success," said Patrick Amstutz, CEO of Molecular Partners. In accordance with Swiss employment law a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. This will include, but will not be limited to, severance packages, and support in seeking new employment, coaching or training opportunities. Molecular Partners foresees the full implementation of these changes enacted by the end of 2025 and the reduction of costs to become fully effective early in 2026. As a result of these headcount reductions, the company now anticipates its cash runway to extend into 2028, beyond its prior guidance of 2027. The strategic review was undertaken to identify certain redundancies within the organization, with a focus on research and associated functions. The company will report its half-year financials on August 25, 2025. Molecular Partners maintains its previously announced timelines with clinical data from both MP0533 and MP0712 expected in H2 2025. About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
